Abstract: A synchronous rectification alternator for a motor vehicle is disclosed. The alternator includes a stator, a rotor, and a synchronous rectification system for rectifying into a DC voltage the alternating voltages supplied by the stator, and a voltage regulator for regulating the DC voltage. The alternator also includes fault detection for detecting faults in the synchronous rectification and supplying fault detection information to the voltage regulator. In one version, the fault information is supplied to the voltage regulator at fault inputs also receiving phase signals representing the alternating voltages supplied by the stator. At least one of the items of fault information is used to cause, in the voltage regulator, opening of an excitation circuit supplying current to an excitation coil of the rotor so as to produce, in the voltage regulator, a fault indication.

Abstract: An alternator includes a stator S, a rotor R and a transistor bridge, which form synchronous rectification. The synchronous rectification is in the form of an over-molded mechatronic housing (2), and the mechatronic housing includes an electronic power substrate (3) and power connection terminals (23), (24). Electronic chips (300A, 300B) are implanted on the electronic power substrate, and at least one of the power connection terminals is connected electrically to the electronic chip by means of at least a first soldered connection wire (300, 301, 302, 30B+, 30B?). According to one embodiment, the electronic power substrate is of the IMS, DBC or PCB type.

Abstract: A synchronous rectification alternator for a motor vehicle is disclosed. The alternator includes a stator, a rotor, and a synchronous rectification system for rectifying into a DC voltage the alternating voltages supplied by the stator, and a voltage regulator for regulating the DC voltage. The alternator also includes fault detection for detecting faults in the synchronous rectification and supplying fault detection information to the voltage regulator. In one version, the fault information is supplied to the voltage regulator at fault inputs also receiving phase signals representing the alternating voltages supplied by the stator. At least one of the items of fault information is used to cause, in the voltage regulator, opening of an excitation circuit supplying current to an excitation coil of the rotor so as to produce, in the voltage regulator, a fault indication.

Abstract: An alternator includes a stator (S), a rotor (R) and a transistor bridge, which form a synchronous rectification. The synchronous rectification is in the form of an over-moulded mecatronic housing (2). The mecatronic housing includes power connection terminals (23, 24), and contains a plurality of electronic power substrates (30, 31, 32) which have the same architecture, and in each of which there is implanted at least a first electronic chip (300A, 300B) of the transistor bridge. According to one embodiment, the electronic power substrate is of the IMS, DBC or PCB type.

Abstract: An alternator includes a stator S, a rotor R and a transistor bridge, which form synchronous rectification. The synchronous rectification is in the form of an over-moulded mecatronic housing (2), and the mecatronic housing includes an electronic power substrate (3) and power connection terminals (23), (24). Electronic chips (300A, 300B) are implanted on the electronic power substrate, and at least one of the power connection terminals is connected electrically to the electronic chip by means of at least a first soldered connection wire (300, 301, 302, 30B+, 30B?). According to one embodiment, the electronic power substrate is of the IMS, DBC or PBC type.

Abstract: The invention relates to compounds having the formula (I): Wherein R1, R2, R3 and R4 are as described herein. Also disclosed are the method of preparation and their use in therapy.

Abstract: The invention relates to compounds having the formula (I): Wherein R1, R2, R3 and R4 are as described herein. Also disclosed are the method of preparation and their use in therapy.

Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

Abstract: The invention relates to substituted (4-phenylpiperazin-1-yl)acylpiperidine derivatives of formula (I) in the form of a base or an addition salt with an acid, and also in the form of a hydrate or solvate, and their preparation process and therapeutic application.

Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4) alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents the aromatic group 1,3-thiazol-2-yl of formula: Preparation process and therapeutic application.

Abstract: The invention relates to substituted (4-phenylpiperazin-1-yl)acylpiperidine derivatives of formula (I) in the form of a base or an addition salt with an acid, and also in the form of a hydrate or solvate, and their preparation process and therapeutic application.

Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4) alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents the aromatic group 1,3-thiazol-2-yl of formula: Preparation process and therapeutic application.

Abstract: The invention relates to novel (aminoalkenyl-benzoyl) benzofuran or benzothiophene derivatives of general formula: These compounds are of use as medicaments, in particular in the treatment of pathological syndromes of the cardiovascular system.

Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

Abstract: The invention relates to novel (aminoalkenyl-benzoyl) benzofuran or benzothiophene derivatives of general formula: 1